Claris to sell injectable drug business and facilities to Baxter

By Gareth Macdonald contact

- Last updated on GMT

Claris to sell injectable drug business and facilities to Baxter

Related tags: Pharmaceutical drug, Mumbai, India

Baxter International has agreed to pay Claris Lifesciences $625m (€598m) for three manufacturing facilities and a portfolio of 11 approved injectable drugs.

The deal – detailed in a Claris filing​ on the Bombay Stock Exchange (BSE) last week – will see Baxter take charge of a $100m a year business, a pipeline of generic injectable drug candidates and production and R&D capabilities.

The three facilities – in Ahmedabad, India – supply injectable drug products to India and a number of international markets, including the US. They also house R&D laboratories.

The US drug firm will install new technologies and make strategic investments at the three plants, explaining that the aim is to launch seven to nine injectable drug products annually by 2019.

Speculation Claris was looking to sell its injectable drug business – and that Baxter had expressed an interest – emerged in August, prompting the Indian firm to issue a denial​. 

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...